Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Go back to Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma| Merck & Co. (NYSE: MRK) | Delayed: 113.87 -1.57 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.44 | 52 Week High | $65.46 | |||
| Open | $114.64 | 52 Week Low | $47.97 | |||
| Day High | $114.94 | P/E | 77.46 | |||
| Day Low | $111.57 | EPS | $1.47 | |||
| Volume | 29,522,568 | |||||
